NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro R&D Day – Presentation
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
– Company announces U.S. FDA clearance of Investigational New Drug (IND) application for STRO-004, its potential best-in-class Tissue Factor ADC; Expects to dose first patient before year-end – – Company presented new preclinical data at World ADC and SITC,...
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025
SOUTH SAN FRANCISCO, Calif., November 5, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a virtual Research &...
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
SOUTH SAN FRANCISCO, Calif., November 3, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 16th Annual World ADC...
Whitepaper: The Power of Partnership in Advancing Innovation
Sutro Biopharma and Boehringer Ingelheim collaborate to scale-up a novel cell-free technology platform to produce ADCs. Explore how cell-free ADC manufacturing is shaping cancer therapy.
Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones
SOUTH SAN FRANCISCO, Calif., September 29, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced an organizational restructuring to prioritize...
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
– On track to initiate FIH study with STRO-004, potential best-in-class Tissue Factor ADC, in the second half of 2025 – – Expanded breadth of preclinical data across pipeline, including STRO-006 and dual-payload ADCs – – Entered research collaboration with the FDA to...
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
SOUTH SAN FRANCISCO, Calif., July 22, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the...
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., June 2, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial...